Riverside Hospital's Pharmacy Services Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Pharmacy operating costs: $14.2M annually (Exhibit 2).
Outsourced vendor bid: $12.8M annually, promising 10% reduction (Para 14).
Drug spend: $8.4M, representing 59% of total pharmacy budget (Exhibit 2).
Staffing costs: $4.1M, including benefits (Exhibit 2).

Operational Facts

Current status: In-house pharmacy operations at Riverside Hospital.
Service levels: Inpatient drug distribution, clinical pharmacist support, and medication reconciliation (Para 5).
Staffing: 32 FTEs, including 8 pharmacists and 24 pharmacy technicians (Exhibit 3).
Performance: 98.2% accuracy rate in medication dispensing (Para 8).

Stakeholder Positions

Dr. Aris (CEO): Focused on bottom-line cost reduction to offset declining Medicare reimbursements (Para 3).
Sarah Jenkins (Director of Pharmacy): Argues that in-house control ensures clinical quality and patient safety (Para 12).
Nursing Staff: Concerned about potential delays in medication delivery if an external vendor is used (Para 18).

Information Gaps

Specific terms of the vendor contract regarding service level agreements (SLAs) or penalty clauses for delays.
Detailed breakdown of the 10% projected savings — specifically whether these come from wage suppression or drug procurement efficiencies.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

Should Riverside Hospital outsource pharmacy operations to reduce costs, or maintain in-house control to preserve clinical quality and operational agility?

Structural Analysis

Value Chain: The pharmacy is a support activity critical to patient outcomes. Outsourcing shifts the primary lever from clinical integration to procurement-driven cost control.
Porter’s Five Forces: Supplier power (drug manufacturers) is high. The hospital lacks the scale to negotiate pricing independently, which is the primary driver for the outsourcing proposal.

Strategic Options

Option 1: Full Outsourcing. Contract with the vendor for $12.8M. Trade-offs: Immediate $1.4M savings, but loss of direct management over clinical staff and potential friction with nursing. Requirements: Legal oversight of contract, transition management.
Option 2: Hybrid Optimization. Retain in-house clinical pharmacy services but outsource drug procurement to a Group Purchasing Organization (GPO). Trade-offs: Keeps staff morale high; captures bulk pricing benefits. Requirements: Negotiating GPO access, internal process audit.
Option 3: Status Quo. Maintain current operations. Trade-offs: Avoids transition risk, but neglects the mandate to address fiscal deficits. Requirements: None.

Preliminary Recommendation

Pursue Option 2. Outsourcing clinical operations creates a cultural and operational divide that poses risks to patient safety. Capturing the savings through procurement efficiencies achieves the financial goal without sacrificing the primary care mission.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Month 1-2: Conduct an audit of current drug procurement channels and identify GPO alternatives.
Month 3: Negotiate GPO participation to lower the $8.4M drug spend.
Month 4: Implement internal process improvement for inventory management to reduce waste, targeting a 3% reduction in overhead.

Key Constraints

Clinical Integration: Pharmacy staff must remain aligned with nursing protocols. Any shift in workflow must be co-designed by both departments.
Vendor Reliability: If drug procurement is outsourced, the primary risk is supply chain disruption. A backup vendor is mandatory.

Risk-Adjusted Implementation

Instead of a full transition, pilot the new procurement process for high-volume, low-risk medications. This creates a feedback loop to monitor performance before full-scale adoption. If savings fall below 5% of the drug spend, re-evaluate the full outsourcing contract.

4. Executive Review and BLUF (Executive Critic)

BLUF

Riverside Hospital should reject full outsourcing. The $1.4M in potential savings is dwarfed by the risk of clinical service degradation. The analysis correctly identifies that the cost problem is concentrated in drug procurement, not labor. Management must transition to a Group Purchasing Organization to capture scale-based savings while maintaining control over clinical staff. Full outsourcing is a blunt instrument for a surgical problem.

Dangerous Assumption

The assumption that a third-party vendor can achieve identical clinical accuracy (98.2%) while reducing costs by 10% without cutting corners in staffing or inventory quality.

Unaddressed Risks

Clinical Liability: If medication errors increase post-outsourcing, the hospital remains the primary bearer of legal and reputational risk.
Cultural Erosion: Outsourcing critical support functions often leads to talent attrition among high-performing pharmacists who value the mission-driven environment.

Unconsidered Alternative

Forming a regional pharmacy consortium with neighboring non-competing hospitals to increase purchasing volume, effectively creating an in-house GPO without ceding control to a commercial vendor.